324 related articles for article (PubMed ID: 33887721)
21. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience.
Özdel Öztürk B; Yavuz Z; Aydın Ö; Mungan D; Sin BA; Demirel YS; Bavbek S
Int Arch Allergy Immunol; 2022; 183(12):1281-1290. PubMed ID: 36126640
[TBL] [Abstract][Full Text] [Related]
22. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
Bettiol A; Urban ML; Dagna L; Cottin V; Franceschini F; Del Giacco S; Schiavon F; Neumann T; Lopalco G; Novikov P; Baldini C; Lombardi C; Berti A; Alberici F; Folci M; Negrini S; Sinico RA; Quartuccio L; Lunardi C; Parronchi P; Moosig F; Espígol-Frigolé G; Schroeder J; Kernder AL; Monti S; Silvagni E; Crimi C; Cinetto F; Fraticelli P; Roccatello D; Vacca A; Mohammad AJ; Hellmich B; Samson M; Bargagli E; Cohen Tervaert JW; Ribi C; Fiori D; Bello F; Fagni F; Moroni L; Ramirez GA; Nasser M; Marvisi C; Toniati P; Firinu D; Padoan R; Egan A; Seeliger B; Iannone F; Salvarani C; Jayne D; Prisco D; Vaglio A; Emmi G;
Arthritis Rheumatol; 2022 Feb; 74(2):295-306. PubMed ID: 34347947
[TBL] [Abstract][Full Text] [Related]
23. Update on eosinophilic granulomatosis with polyangiitis.
Furuta S; Iwamoto T; Nakajima H
Allergol Int; 2019 Oct; 68(4):430-436. PubMed ID: 31266709
[TBL] [Abstract][Full Text] [Related]
24. Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
Son H; Lee WJ; Moon J; Yoon S; Jung KH; Park KI; Lee SK; Chu K
J Neuroimmunol; 2021 Jun; 355():577551. PubMed ID: 33773378
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.
Pradhan RR; Nepal G; Mandal S
Pulm Med; 2019; 2019():4376380. PubMed ID: 30941214
[TBL] [Abstract][Full Text] [Related]
26. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
27. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
[TBL] [Abstract][Full Text] [Related]
28. Increased Circulating Cell-Free DNA in Eosinophilic Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and Immunothrombosis.
Hashimoto T; Ueki S; Kamide Y; Miyabe Y; Fukuchi M; Yokoyama Y; Furukawa T; Azuma N; Oka N; Takeuchi H; Kanno K; Ishida-Yamamoto A; Taniguchi M; Hashiramoto A; Matsui K
Front Immunol; 2021; 12():801897. PubMed ID: 35095884
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study.
Ueno M; Miyagawa I; Aritomi T; Kimura K; Iwata S; Hanami K; Fukuyo S; Kubo S; Miyazaki Y; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2022 Jun; 24(1):159. PubMed ID: 35768825
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468
[TBL] [Abstract][Full Text] [Related]
31. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
Ennis D; Lee JK; Pagnoux C
Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
[TBL] [Abstract][Full Text] [Related]
32. A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Quan MV; Frankel SK; Maleki-Fischbach M; Tan LD
BMC Pulm Med; 2018 Nov; 18(1):181. PubMed ID: 30497438
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.
Teixeira V; Mohammad AJ; Jones RB; Smith R; Jayne D
RMD Open; 2019; 5(1):e000905. PubMed ID: 31245051
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
[TBL] [Abstract][Full Text] [Related]
35. Updates for the treatment of EGPA.
Raffray L; Guillevin L
Presse Med; 2020 Oct; 49(3):104036. PubMed ID: 32652104
[TBL] [Abstract][Full Text] [Related]
36. A case of eosinophilic polyangiitis with granulomatosis that evolved to cardiac arrest due to advanced atrioventricular block.
Sakurai Y; Oshikata C; Katayama T; Takagi S; Kaneko Y; Yo K; Kaneko T; Kubota H; Matsubara T; Tsurikisawa N
Nagoya J Med Sci; 2023 Feb; 85(1):171-178. PubMed ID: 36923623
[TBL] [Abstract][Full Text] [Related]
37. Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
Pouliquen IJ; Austin D; Steinfeld J; Yancey SW
Clin Ther; 2021 Jul; 43(7):1278-1280. PubMed ID: 34187697
[No Abstract] [Full Text] [Related]
38. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis.
Vultaggio A; Nencini F; Bormioli S; Vivarelli E; Dies L; Rossi O; Parronchi P; Maggi E; Matucci A
Allergy Asthma Immunol Res; 2020 Sep; 12(5):885-893. PubMed ID: 32638567
[TBL] [Abstract][Full Text] [Related]
39. Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis.
Nakamura Y; Fukutomi Y; Sekiya K; Kajiwara K; Kawasaki Y; Fujita N; Nagayama K; Iwata M; Iwamoto K; Yano K; Hamada Y; Watai K; Ryu K; Hayashi H; Kamide Y; Taniguchi M
Mod Rheumatol; 2022 Feb; 32(2):387-395. PubMed ID: 34910206
[TBL] [Abstract][Full Text] [Related]
40. [Steroids-Resistant EGPA-Induced Neuropathy with Acute Disease Progression: How to Use Mepolizumab as Novel Targeted Agent].
Hattori N
Brain Nerve; 2022 May; 74(5):531-536. PubMed ID: 35589643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
